Other substances

mNb6-tri

A trimeric anti-spike protein (SARS-CoV-2) nanobody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

mNb6-tri is a trimeric synthetic nanobody with femtomolar affinity for the SARS-CoV-2 spike protein and capability of neutralization of SARS-CoV-2 infection at picomolar concentrations. Its monomeric parent was identified using a yeast surface-displayed library in a screening for a SARS-CoV-2 spike protein-hACE2 disruptor (Schoof et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
Spike protein Biophysical assay In vitro Antibody 		in vitro biophysical assay; hACE2 HEK293 cells; Vero E6 cells 41.85

The nanobody recognizes RBD epitopes and potently binds the SARS-CoV-2 spike protein. It inhibits pseudovirus and live virus infection in low nanomolar concentrations in vitro. The nanobody is stable and does not form aggregates.

 Nov/05/2020
Export (.csv)